Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study
Top Cited Papers
- 9 November 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (16), 1667-1676
- https://doi.org/10.1016/s1470-2045(15)00361-7
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysisLaboratory Investigation, 2011
- A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without ScreeningCancer Epidemiology, Biomarkers & Prevention, 2011
- Polygenic Risk Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort StudyEuropean Urology, 2011
- Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control studyBMJ, 2010
- Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate CancerClinical Cancer Research, 2009
- Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancerCurrent Opinion in Urology, 2009
- Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study DesignJNCI Journal of the National Cancer Institute, 2008
- H6D Polymorphism in Macrophage-Inhibitory Cytokine-1 Gene Associated With Prostate CancerJNCI Journal of the National Cancer Institute, 2004
- The Influence of Finasteride on the Development of Prostate CancerNew England Journal of Medicine, 2003
- Better Bootstrap Confidence IntervalsJournal of the American Statistical Association, 1987